logo
logo
Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc.

NASDAQ•OBIO
CEO: Mr. David P. Hochman
セクター: Healthcare
業種: Biotechnology
上場日: 2020-08-04
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
連絡先情報
150 Union Square Drive, New Hope, PA, 18938, United States
212-862-5797
orchestrabiomed.com
時価総額
$216.26M
PER (TTM)
-2.0
34.3
配当利回り
--
52週高値
$5.98
52週安値
$2.20
52週レンジ
43%
順位49Top 66.7%
3.2
F-Score
改良版 Piotroski 分析
5年ファンダメンタル
弱い • 3.2 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2021-2025

財務ダッシュボード

Q3 2025 データ

売上高

$861.00K-12.77%
直近4四半期の推移

EPS

-$0.40-2.44%
直近4四半期の推移

フリーCF

-$14.86M+7.93%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Partnership Revenue Growth Partnership revenue grew 10% to $2.1M for nine months ended September 30, 2025. Total revenue reached $2.565M, up 8%.
Strong Financing Inflows Net cash provided by financing activities totaled $75.7M, driven by stock sales and royalty proceeds. Cash reserves stand at $95.8M.
Royalty Funding Secured Received $20.0M investment from Ligand via Royalty Purchase Agreement in August 2025. Total cash and marketable securities $95.8M.
Cash Position Strengthened Cash and equivalents ended period at $42.0M; total cash and marketable securities reached $95.8M on September 30, 2025.

リスク要因

Operating Losses Widening Net loss expanded 31% to $58.9M for nine months ended September 30, 2025. Accumulated deficit reached $368.8M.
Increased R&D Investment Research and development expenses increased 30% to $41.4M for nine months, driven by BACKBEAT and Virtue Trial support.
Terumo Revenue Decline Quarterly partnership revenue fell 10% sequentially to $721K as Terumo Agreement terminated in October 2025.
Liquidity Dependent on Capital Operations funded primarily through equity issuances; future spending requires additional capital raises to meet funding needs.

見通し

Virtue Trial Enrollment Starts First patient enrolled in Virtue SAB pivotal trial in October 2025; completion currently planned for mid-2027.
Terumo Agreement Terminated Terminated Terumo Agreement; retained all rights for non-ISR indications; received $10.0M termination fee.
New Preferred Stock Issued Issued $20.0M Series A Preferred Stock in November 2025; conversion price based on $12.00 floor or 20% discount.
Increased Future Spending Expect research and development expenses to increase in absolute dollars developing new products and expanding operations.

同業比較

売上高 (TTM)

Enanta Pharmaceuticals, Inc.ENTA
$66.98M
+0.6%
Codexis, Inc.CDXS
$52.93M
-17.9%
Invivyd, Inc.IVVD
$50.04M
+332.7%

粗利益率 (最新四半期)

Sangamo Therapeutics, Inc.SGMO
100.0%
+0.0pp
Orchestra BioMed Holdings, Inc.OBIO
94.3%
+1.2pp
Invivyd, Inc.IVVD
91.7%
+0.4pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
ENTA$321.55M-5.6-78.6%17.3%
IVA$320.73M-1.9536.4%32.0%
EPRX$281.90M-10.9-62.6%0.2%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
50.4%
高成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月30日
|
EPS:-$0.38
|
売上高:-
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月10日|
    売上高: $861.00K-12.8%
    |
    EPS: $-0.40-2.4%
    予想を上回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月12日|
    売上高: $836.00K+7.5%
    |
    EPS: $-0.50+11.1%
    予想を上回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月12日|
    売上高: $868.00K+40.0%
    |
    EPS: $-0.49+28.9%
    予想を上回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年3月31日|
    売上高: $2.64M-4.4%
    |
    EPS: $-1.66-12.2%
    予想通り

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月12日|
    売上高: $987.00K+135.6%
    |
    EPS: $-0.41+7.9%
    予想を上回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月12日|
    売上高: $778.00K-15.0%
    |
    EPS: $-0.45+28.6%
    予想を下回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月13日|
    売上高: $620.00K-46.7%
    |
    EPS: $-0.38-5.0%
    予想通り

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年3月27日|
    売上高: $2.76M-21.9%
    |
    EPS: $-1.48-12.1%
    予想通り